World's Best Scientists 2026 revealed!
Carsten Müller-Tidow

Carsten Müller-Tidow

D-Index & Metrics

Medicine

D-Index
91
Citations
32081
World Ranking
11714
National Ranking
636

Overview

Carsten Müller-Tidow is affiliated with the University Hospital Heidelberg in Germany. Their research focuses primarily on fields within medicine, including extensive work in hematology, molecular biology, oncology, immunology, and genetics.

The scientist's recent published papers highlight key areas of interest and ongoing investigations:

  • Side-effect management of chimeric antigen receptor (CAR) T-cell therapy, 2020, Annals of Oncology
  • CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity, 2021, Blood
  • The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients, 2023, Cancer Cell
  • A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy, 2023, Nature Medicine
  • Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states, 2021, Nature Immunology

Frequent co-authors that have collaborated with Carsten Müller-Tidow include:

  • Hubert Serve
  • Peter Dreger
  • Christoph Röllig
  • Uwe Platzbecker
  • Claudia D. Baldus

Publication venues where their work appears recurrently include:

  • Blood
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HemaSphere
  • Leukemia
  • Clinical Lymphoma Myeloma & Leukemia

The scientist's research integrates several major topics within their fields of study:

  • Acute Myeloid Leukemia Research
  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Protein Degradation and Inhibitors
  • Immune Cell Function and Interaction

Within the subfields, Carsten Müller-Tidow's work spans:

  • Hematology
  • Molecular Biology
  • Oncology
  • Immunology
  • Genetics

Their studies have contributed to understanding the management of CAR T-cell therapies, immune cell interactions, and advances in leukemia and myeloma treatments. Their interdisciplinary approach merges clinical and molecular perspectives, supporting progress in personalized medicine approaches to hematologic malignancies.

Best Publications

  • MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

    Ping Ji;Sven Diederichs;Wenbing Wang;Sebastian Böing

  • Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

    Tino Schenk;Weihsu Claire Chen;Stefanie Göllner;Louise Howell

  • The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.

    Lars Henning Schmidt;Tilmann Spieker;Steffen Koschmieder;Julia Humberg

  • Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

    Ashley Hamilton;G. Vignir Helgason;Mirle Schemionek;Bin Zhang

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney

  • Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

    Chantana Polprasert;Isabell Schulze;Mikkael Sekeres;Hideki Makishima

  • Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

    Thomas Büchner;Wolfgang E. Berdel;Claudia Haferlach;Torsten Haferlach

  • Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells

    Carsten Müller-Tidow;Björn Steffen;Thomas Cauvet;Lara Tickenbrock

  • Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

    Hubert Serve;Utz Krug;Ruth Wagner;M. Cristina Sauerland

  • Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

    Chunaram Choudhary;Jesper V. Olsen;Jesper V. Olsen;Christian Brandts;Jürgen Cox

  • Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

    Masao Mizuki;Joachim Schwäble;Joachim Schwäble;Joachim Schwäble;Claudia Steur;Claudia Steur;Claudia Steur;Chunaram Choudhary;Chunaram Choudhary;Chunaram Choudhary

  • EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

    Günther H. S. Richter;Stephanie Plehm;Annette Fasan;Sabine Rössler

  • Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages

    Daniel Baitsch;Hans H. Bock;Thomas Engel;Ralph Telgmann

  • Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia

    John A. Pulikkan;Viola Dengler;Philomina S. Peramangalam;Abdul A. Peer Zada

  • Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

    Utz Krug;Christoph Röllig;Anja Koschmieder;Achim Heinecke

  • Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.

    M.-L. Schubert;M. Schmitt;L. Wang;C.A. Ramos

  • AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

    Chunaram Choudhary;Joachim Schwäble;Joachim Schwäble;Christian Brandts;Christian Brandts;Lara Tickenbrock;Lara Tickenbrock

  • The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

    Bryan Linggi;Carsten Müller-Tidow;Louis van de Locht;Ming Hu

  • Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

    Christian H. Brandts;Bülent Sargin;Miriam Rode;Christoph Biermann

  • EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

    S Plehm;A Fasan;S Rössler;R Unland

Frequent Co-Authors

Wolfgang E. Berdel
Wolfgang E. Berdel University of Münster
Hubert Serve
Hubert Serve Goethe University Frankfurt
Martin Dugas
Martin Dugas Heidelberg University
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Sven Diederichs
Sven Diederichs German Cancer Research Center
Daniel G. Tenen
Daniel G. Tenen National University of Singapore
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering other routes to a healthcare career? There are several online degree programs that can help you advance in the medical field—even for those who do not follow the traditional medical school path.

Many students choose nursing as an alternative, thanks to its flexible degree options and rewarding career prospects. If affordability is a top concern, check out what is the cheapest online college for nursing? to find programs that fit your budget.

Already an RN? Earning a BSN can boost your career and earning potential. Explore the cheapest rn to bsn online programs available if you’re looking for flexible and affordable advancement.

For those interested in research, teaching, or advanced clinical practice, numerous online phd programs in nursing offer a convenient pathway to the highest academic credentials in nursing.

Even non-nurses with a bachelor’s degree in another field can enter nursing. Review msn direct entry programs online to find fast-track options designed for career changers.

Each of these online pathways can help you join the healthcare workforce and make a difference, even if you don’t pursue a traditional MD.

Best Scientists Citing Carsten Müller-Tidow

Trending Scientists